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The aim of the present study was to evaluate process variables and intermediate outcomes involved in 
long-term oxygen therapy (LTOT) by concentrator with the purpose of identifying which of those factors 
would be the most influential in the final health outcome of the therapy. A cross-sectional survey was 
carried out on a random sample of 111 patients receiving LTOT by concentrator in Catalonia (Spain). 
Patients were interviewed and assessed at home by a trained physician, and the variables collected were 
arterial oxygen saturation, performance of the concentrators, and patient compliance. Sixty-two patients 
participated in the study. Overall, LTOT was appropriately prescribed in 36 patients, of whom only 29 
were able to correct their level of hypoxaemia. Patient compliance with treatment was considered 
adequate in 19 of those 29 patients. Thus, only 19 of 62 patients (31%) fulfilled those criteria needed to 
achieve the expected clinical benefits. Strategies for improving the effectiveness of medical interventions 
or technologies ought to consider those factors of the therapeutic process which might influence the 
expected health outcomes in a specific health-care context. 
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Introduction 
Technology assessment activities include the 
evaluation of the efficacy, safety, effectiveness 
and appropriateness of emerging and established 
health technologies (1,2). Randomized control 
trials have proved the efficacy of long-term oxy- 
gen therapy (LTOT) as survival rates of patients 
with chronic obstructive pulmonary disease 
(COPD) and chronic respiratory failure were 
shown to increase due to the effect of therapy 
(3,4). However, the effectiveness of any therapy 
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is dependent, in average clinical practice, on the 
achievement of the different intermediate out- 
comes implied in the therapeutic process, along 
with its appropriate indication and use. In 
LTOT, those process variables are the diagnosis 
of chronic hypoxaemia, the correction of the 
hypoxaemia which depends on correct prescrip- 
tion of oxygen flow rate and proper functioning 
of the device, and patient compliance with the 
treatment. All those intermediate factors should 
be met simultaneously in each treated patient in 
order to get the expected health benefit of the 
therapy. Therefore, the effectiveness of LTOT 
depends initially on the appropriateness of the 
therapeutic process. 
The aim of the present study was to evaluate 
process variables and intermediate outcomes 
involved in LTOT by concentrator with the 
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purpose of identifying which of those factors 
would be the most influential in the final out- 
come of the therapy. The questions include: are 
the patients, enrolled in a public financed pro- 
gramme, being prescribed oxygen correctly?, 
are they complying with its use?, are they 
reporting compliance accurately? and, finally, is 
the equipment functioning well? 
Patients and Methods 
In Catalonia (Spain), the total number of 
patients included in the public financed LTOT 
programme was 3910 in 1991 (prevalence rate 
65/100 000). Overall, 534 patients (14%) of those 
patients were receiving LTOT by concentrator. A 
random sample of 111 patients was selected from 
the census of all patients who had received this 
therapy via concentrator during 1991. A cross- 
sectional survey of the 111 patients was carried 
out from March to April 1992. Patients who died 
during the time interval from the census to the 
survey (n=21) or were no longer receiving treat- 
ment (n= 14) were excluded from the study. All 
patients were assessed at home by the same 
trained physician, who was not a member of the 
research team. Each patient provided informed 
consent before participating in the study. 
Data regarding gender and place of residence 
of members of the programme were collected 
from the Catalan Health Service information 
system. A questionnaire was also specifically 
designed to obtain the following information: 
age, smoking habits, main diagnosis, and type 
and hours of concentrator utilization. Level of 
percentage saturation of haemoglobin with oxy- 
gen in arterial blood (,SaO,) at rest was measured 
using a pulse oxymeter (Ohmeda Biox IVA, 
U.K.), firstly whilst breathing room air for 
30 min and, secondly, whilst breathing oxygen at 
the prescribed flow rate for more than 30 min. 
The percentage of oxygen delivered by concen- 
trator was measured at a flow rate of 2 1 min - ’ 
when the device was working for more than 
1.5 min using an Ohmeda 5120. Oxygen Monitor 
(U.K.) indicated oxygen concentrations from 0 
to 100% (drift range f 1%; monitor linearity 
f 1% of full scale). 
The criteria established to define the ap- 
propriateness of the therapeutic process were: 
(1) Diagnosis of chronic hypoxaemia at the 
time of” the survey (SaO, I 88% at rest while 
breathing room air) (5); 
(2) Oxygen flow rate capable of raising 
arterial oxygen tension (PaO,) at rest (SaO, 
>90% at rest whilst breathing oxygen) (6); 
(3) Proper functioning of the concentrator 
(percent of oxygen delivered >90% at a flow rate 
of 2 1 min - ‘) (7); and 
(4) Adequate patient compliance. 
The latter was measured by a clock fitted to 
every device in order to record hours of electric- 
ity used for a period of at least 7 days. Adequate 
compliance was defined as concentrator utiliza- 
tion for at least 80% (2 12 h day - ‘) of the 
previously defined appropriate utilization time 
(215 hday-l). 
Data are expressed as mean f SD. Differences 
between self-reported and measured compliance 
were examined using the McNemar test. A P 
value ~0.05 was considered to be significant. 
Results 
Overall, 76 patients were considered eligible, 
although only 62 participated in the study (82%). 
Reasons for non-participation were change of 
address (nine patients) and hospitalization at 
the time the survey took place (five patients). 
The average age of the participant patients was 
68 f 9 years, 76% were male, 11% of the sur- 
veyed patients were active smokers at the time of 
the study, 60% were ex-smokers, and 29% had 
never smoked. The most frequent diagnosis 
reported was chronic obstructive pulmonary dis- 
ease (70%). In 87% of cases, the therapy had 
been prescribed by chest physicians. 
Inclusion in the LTOT programme was 
considered to be appropriate for only 36 of the 
62 patients assessed at the time of the survey 
(SaO,, 81.0 f 5.8%), while this therapy was 
considered to be inappropriate in the remaining 
26 patients (SaO,, 92.1 + 2.1%). The latter group 
of patients was, therefore, excluded from the 
therapeutic process analysis. In addition, 12 of 
the 62 devices (19O/,) were found not to work 
properly. Defective devices were observed 
mainly in the group in which the therapy was 
inappropriately prescribed (10 of 12 devices). 
Table 1 includes the list of concentrator models 
used. 
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TABLE 1. Concentrator models 
Model Number 
Companion 208 (U.S.A.) 17 
Bunn 3001 (U.S.A.) 16 
DeVilbis (U.S.A.) 13 
Bunn Rx02 (U.S.A.) 9 
Forlip (U.S.A.) 4 
Bunn Lite (U.S.A.) 3 
Total 62 
1 Patients participating in study (n = 62) / 
Satisfactory Unsatisfactory 
19/29 10/29 
Appropriate process 
of LTOT by concentrator 
19162 
FIG. 1. Process variables analysis of long-term 
oxygen therapy (LTOT) via oxygen concentrator, 
Compliance with the therapy was reported 
as adequate by 54 patients (87%), although 
measured compliance was found to be adequate 
in only 38 of those patients (67%). The latter 
group were patients who had used the concen- 
trator for an average of 18.1 i 4.0 h day ~ ‘. The 
group who misreported their compliance (12116) 
had used the therapy for an average of 
8+4&3.4hday-‘. The difference between self- 
reported and measured compliance with the 
therapy was significant (P~0.05). 
Figure 1 summarizes the results of the global 
assessment of the process associated with the 
indication and use of LTOT by concentrator in 
the present series. Key factors of the therapeutic 
process which might modify the effectiveness 
of the therapy were identified and analysed. 
Overall, 29 of the 36 patients in whom LTOT 
had been appropriately prescribed were able 
to correct their level of hypoxaemia (SaO, 
94.0 ic 2.0%) using the device at the prescribed 
flow rate. Of those 29 patients, 19 received 
oxygen for more than 12 h day - t as measured 
by the device’s clock. Therefore, the therapy was 
prescribed and used appropriately in only 19 of 
the 62 patients. 
Discussion 
The results of this study indicate that LTOT via 
oxygen concentrator was prescribed and used 
appropriately in only 31% of the patients who 
were enrolled in the programme. Therefore, the 
overall effectiveness of the therapy might have 
been affected by a non-appropriate prescription, 
an incorrectly prescribed flow rate, an improper 
performance of the device, and/or a low patient 
compliance. Some studies have analysed the 
influence of all these factors independently 
(X-11). However, this is the first time that these 
factors have been considered simultaneously in a 
single sample of patients. The first therapeutic 
factor to be considered in the assessment of the 
therapeutic process was the appropriateness of 
the prescription. Pulse oxymetry does not 
replace arterial blood gas measurements in the 
indication of LTOT; however, since the error in 
the accuracy and the precision in most pulse 
oxymeters is smaller than 3% (12), it is accept- 
able to consider that patients with a SaO, of 
8 1.0 i 5.8% have a sufficient level of hypoxaemia 
to justify home oxygen therapy. One of the 
indications for home oxygen therapy accepted 
by Medicare is &‘aO, I 88% (13). The results of 
the present study showed that LTOT by concen- 
trator were not prescribed in accordance with 
well-established prescription criteria (14) in 42% 
of the study patients. 
A second factor that might have influenced the 
appropriateness of the process was the capability 
of the device to correct the baseline level of 
hypoxaemia. Only 29 of 36 patients who fulfilled 
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established criteria for the appropriate prescrip- 
tion of the therapy were able to correct their 
hypoxaemia levels. Failure to raise PaO, to 
therapeutic levels may have been a consequence 
of either an incorrectly prescribed oxygen flow 
rate (n= 5) or a poor device performance (n=2). 
Overall, concentrators did not work properly in 
19% of the entire sample, a figure which is 
similar to that observed in France (15). Concen- 
trators have been used in Catalonia as an oxygen 
source since 1984 (16). At the time of the present 
study, there was a regulation from the local 
health authorities which aimed to ensure the 
periodical control of home oxygen therapy com- 
pliance (by checking the concentrator timer), but 
it did not explicitly oblige the providers to make 
periodical inspections of the device functioning. 
The fact that almost 20% of all devices did not 
work properly can be used to support the notion 
that oxygen concentrators should be equipped 
with alarms to detect failures in the delivery of 
oxygen concentration. Also, quality control 
strategies to detect these failures must be imple- 
mented. The number of patients using concen- 
trators in Catalonia has progressively increased. 
One year after the present study was undertaken, 
23% of the patients on LTOT used this oxygen 
source, and the percentage of patients using 
concentrators fulfilling the indication for LTOT 
was higher than the population of patients with 
LTOT supplied by cylinders (17). 
The last factor related to the therapeutic 
process that should be considered is patient 
compliance with therapy. According to differ- 
ent published studies, the percentage of non- 
complaints can range from 36 to 62% (l&19). 
In the present study, measured compliance 
(61%) was lower than self-reported compliance 
(87%). 
The results of the present study showed that 
only one out of three patients who were enrolled 
in the LTOT programme via concentrator might 
have received its expected clinical benefits. In- 
appropriate prescription appears to be a key 
factor on the inappropriateness of the therapeu- 
tic process in Catalonia. Nevertheless, appro- 
priateness might also be improved if faulty 
concentrators were detected and patient adher- 
ence to the therapy was increased. This study 
was part of a preliminary effort (20) to re- 
organize the prescription of LTOT in Catalonia. 
The objective of this work was not to decide 
whether LTOT was to be maintained or not; this 
should be made by the physician in charge. The 
authors’ aim was to generate objective informa- 
tion, regarding the environment, to be used 
to elaborate recommendations for clinicians, 
health-care providers and administrators. 
In patients with underlying chronic condi- 
tions, factors related to the therapeutic process 
must be re-assessed periodically if the effective- 
ness of the therapy is to be guaranteed (21). 
This study showed how therapeutic process 
variables, which might be more easily con- 
trolled in a randomized control trial but not in 
average clinical practice, might distort the true 
effect of the therapy and, therefore, modify its 
expected effectiveness. The present results indi- 
cate that, in the context of the Catalan Health 
Service, efforts directed towards improving 
adherence to well-designed clinical practice 
guidelines for the appropriate prescription of 
the therapy might have more effect on the 
overall effectiveness than efforts directed to 
improve patient compliance alone. The latter 
might be the implementation of quality control 
measures to detect faulty devices. 
This type of technology assessment study can 
provide the objective information needed to 
design strategies to improve the therapeutic pro- 
cess and, thereby, the effectiveness of LTOT in 
COPD patients. 
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